OBI Pharma, Inc., is a Taiwan based bio-pharma company founded in 2002. Its mission is to improve health and the quality of life through innovative cancer therapeutics. OBI seeks to develop and license novel therapeutic agents for unmet medical needs, including cancer by targeting the Globo Series antigens, the AKR1C3 enzyme, and other promising targets. The company’s leading compound is Adagloxad Simolenin (formerly OBI-822), a late-stage novel active immune-oncology (I/O) Globo Series-based therapeutic vaccine for the treatment of epithelial cancers, such as breast, ovarian, lung, prostate, colon, gastric, and pancreatic cancer.
OBI has a unique pipeline of active (vaccines) and passive (mAb & ADC) I/O therapies. In addition to Adagloxad Simolenin, OBI is currently developing OBI-833, a Globo Series cancer vaccine for epithelial cancers other than breast and ovarian cancer. To further enrich its product pipeline, OBI is developing OBI-888, a Globo H-based monoclonal antibody, and OBI-999, a conjugated Globo Series antibody (ADC) for multiple cancers. OBI is also developing OBI-3424, a novel First-in-Class compound targeting multiple cancers (liquid and solid) that express the AKR13C enzyme.OBI is publicly listed on the Taipei Exchange (證券櫃檯買賣中心) with Stock Code 4174. It has established wholly-owned subsidiaries in the US and China. The company is led by a management team with a track record of success in new drug development and commercialization.